Chronic lymphocytic leukemia · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cyclophosphamide and Fludarabine (FC) Variant #15 | — | R 14 005 | — | 19.7 mo | — | 8 | R 112 036 PFS proxy | 2 |
Fludarabine monotherapy Variant #05 | — | R 13 754 | 28d | ~16.5 mo | ~52.9 mo | ~12 | ~R 165 047 PFS proxy · indirect | 3 |
CAP Variant #01 | — | R 709 | 30d | — | — | ~6 | ~R 4 256 indirect | — |
HDMP Variant #01 Partial | — | — | 35d | — | — | ~1 | — | — |
Tisagenlecleucel monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
5 of 5 regimens shown